Despite advances in the treatment of gynaecological malignancies, both recurrent endometrial and cervical cancers when not amenable to localised therapy (surgery or radiotherapy), remain incurable with limited prognosis and effective treatment options. Chemotherapy remains the standard of care for women with metastatic endometrial or cervical cancers. The addition of bevacizumab to first-line chemotherapy for metastatic cervical cancer patients represents a significant step forward in improving survival. More recently, immunotherapeutic strategies targeting the PD-1/-L1 pathway have shown clinical activity in both endometrial and cervical cancers. The increased understanding of the molecular biology of these cancers is shaping target-specific treatments. Here we summarise current treatment options and results from clinical trials of immunotherapy and other targeted therapies that have already changed, or have the potential to change, clinical practice in metastatic/recurrent endometrial and cervical cancer.

尽管妇科恶性肿瘤的治疗取得了进展，但在不适合局部治疗（手术或放疗）的情况下，复发性子宫内膜癌和宫颈癌仍然无法治愈，预后和有效治疗选择有限。化疗仍然是患有转移性子宫内膜癌或宫颈癌的女性的标准治疗方法。在转移性宫颈癌患者的一线化疗中加入贝伐单抗代表着在提高生存率方面向前迈出了重要一步。最近，针对 PD-1/-L1 通路的免疫治疗策略已在子宫内膜癌和宫颈癌中显示出临床活性。对这些癌症分子生物学的更多了解正在塑造特定目标的治疗方法。